BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 24594697)

  • 21. Differential estrogen-regulation of CXCL12 chemokine receptors, CXCR4 and CXCR7, contributes to the growth effect of estrogens in breast cancer cells.
    Boudot A; Kerdivel G; Habauzit D; Eeckhoute J; Le Dily F; Flouriot G; Samson M; Pakdel F
    PLoS One; 2011; 6(6):e20898. PubMed ID: 21695171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer.
    Nazari A; Khorramdelazad H; Hassanshahi G
    Int J Clin Oncol; 2017 Dec; 22(6):991-1000. PubMed ID: 29022185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CXCL12-CXCR7 axis contributes to the invasive phenotype of pancreatic cancer.
    Guo JC; Li J; Zhou L; Yang JY; Zhang ZG; Liang ZY; Zhou WX; You L; Zhang TP; Zhao YP
    Oncotarget; 2016 Sep; 7(38):62006-62018. PubMed ID: 27542220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression.
    Sun X; Cheng G; Hao M; Zheng J; Zhou X; Zhang J; Taichman RS; Pienta KJ; Wang J
    Cancer Metastasis Rev; 2010 Dec; 29(4):709-22. PubMed ID: 20839032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists.
    Morimoto M; Matsuo Y; Koide S; Tsuboi K; Shamoto T; Sato T; Saito K; Takahashi H; Takeyama H
    BMC Cancer; 2016 May; 16():305. PubMed ID: 27175473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inflammatory CXCL12-CXCR4/CXCR7 axis mediates G-protein signaling pathway to influence the invasion and migration of nasopharyngeal carcinoma cells.
    Qiao N; Wang L; Wang T; Li H
    Tumour Biol; 2016 Jun; 37(6):8169-79. PubMed ID: 26715277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected Patients.
    D'Alterio C; Giardino A; Scognamiglio G; Butturini G; Portella L; Guardascione G; Frigerio I; Montella M; Gobbo S; Martignoni G; Napolitano V; De Vita F; Tatangelo F; Franco R; Scala S
    Cells; 2022 Oct; 11(21):. PubMed ID: 36359736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prognostic significance and impact of the CXCR4-CXCR7-CXCL12 axis in primary cutaneous melanoma.
    McConnell AT; Ellis R; Pathy B; Plummer R; Lovat PE; O'Boyle G
    Br J Dermatol; 2016 Dec; 175(6):1210-1220. PubMed ID: 27167239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CXCR4 in Tumor Epithelial Cells Mediates Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma.
    Morita T; Kodama Y; Shiokawa M; Kuriyama K; Marui S; Kuwada T; Sogabe Y; Matsumori T; Kakiuchi N; Tomono T; Mima A; Ueda T; Tsuda M; Yamauchi Y; Nishikawa Y; Sakuma Y; Ota Y; Maruno T; Uza N; Nagasawa T; Chiba T; Seno H
    Cancer Res; 2020 Oct; 80(19):4058-4070. PubMed ID: 32606001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CXCL12 receptor preference, signal transduction, biological response and the expression of 5T4 oncofoetal glycoprotein.
    McGinn OJ; Marinov G; Sawan S; Stern PL
    J Cell Sci; 2012 Nov; 125(Pt 22):5467-78. PubMed ID: 22956548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imaging ligand-dependent activation of CXCR7.
    Luker KE; Gupta M; Steele JM; Foerster BR; Luker GD
    Neoplasia; 2009 Oct; 11(10):1022-35. PubMed ID: 19794961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The CXCL12/CXCR7 signalling axis promotes proliferation and metastasis in cervical cancer.
    Xu L; Li C; Hua F; Liu X
    Med Oncol; 2021 Apr; 38(5):58. PubMed ID: 33847822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression and functional heterogeneity of chemokine receptors CXCR4 and CXCR7 in primary patient-derived glioblastoma cells.
    Liu C; Pham K; Luo D; Reynolds BA; Hothi P; Foltz G; Harrison JK
    PLoS One; 2013; 8(3):e59750. PubMed ID: 23555768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proinflammatory CXCL12-CXCR4/CXCR7 Signaling Axis Drives Myc-Induced Prostate Cancer in Obese Mice.
    Saha A; Ahn S; Blando J; Su F; Kolonin MG; DiGiovanni J
    Cancer Res; 2017 Sep; 77(18):5158-5168. PubMed ID: 28687617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Constitutive CXCL12 expression induces anoikis in colorectal carcinoma cells.
    Wendt MK; Drury LJ; Vongsa RA; Dwinell MB
    Gastroenterology; 2008 Aug; 135(2):508-17. PubMed ID: 18558091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma.
    Li T; Li H; Wang Y; Harvard C; Tan JL; Au A; Xu Z; Jablons DM; You L
    J Pathol; 2011 Mar; 223(4):519-30. PubMed ID: 21294125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CXCL12-CXCR4/CXCR7 axis contributes to cell motilities of oral squamous cell carcinoma.
    Chen N; Jiang X; Wang J; Wu T; Cheng B; Xia J
    Tumour Biol; 2016 Jan; 37(1):567-75. PubMed ID: 26232325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression and function of CXCL12/CXCR4/CXCR7 in thyroid cancer.
    Zhu X; Bai Q; Lu Y; Lu Y; Zhu L; Zhou X; Wu L
    Int J Oncol; 2016 Jun; 48(6):2321-9. PubMed ID: 27082011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CXCL12/CXCR4 protein signaling axis induces sonic hedgehog expression in pancreatic cancer cells via extracellular regulated kinase- and Akt kinase-mediated activation of nuclear factor κB: implications for bidirectional tumor-stromal interactions.
    Singh AP; Arora S; Bhardwaj A; Srivastava SK; Kadakia MP; Wang B; Grizzle WE; Owen LB; Singh S
    J Biol Chem; 2012 Nov; 287(46):39115-24. PubMed ID: 22995914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CXCL12-CXCR4 promotes proliferation and invasion of pancreatic cancer cells.
    Shen B; Zheng MQ; Lu JW; Jiang Q; Wang TH; Huang XE
    Asian Pac J Cancer Prev; 2013; 14(9):5403-8. PubMed ID: 24175834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.